Not Yet RecruitingNot Applicable

Investigation of an Intelligent Centre-adaptive Multi-modal Fusion Framework (Cad- MMFF) to Overcome Unnecessary Prostate Biopsies and Optimize MRI Utilization

Hong Kong400 participantsStarted 2026-09-01

Plain-language summary

This study aims to investigate a novel Centre-Adaptive Multi-Modal Fusion Framework (Cad-MMFF) that integrates clinical, ultrasound, and MRI data to improve the detection of clinically significant prostate cancer (csPCa), reduce unnecessary biopsies, and optimize MRI utilization.

Who can participate

Age range

45 Years

Sex

MALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Ethnically Chinese men aged ≥ 50 * Suspicion of PCa \[elevated PSA (\>4-ng/ml) or abnormal DRE/PHI\] and indicated for prostate biopsy * Obtained clinical consent (for prospectively enrolled patients only) Exclusion Criteria: * Prior biopsy/treatments for PCa * History of genitourinary cancer * Poor image quality * Incomplete imaging scans/clinical data/pathological results

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Area under Receiver-Operating-Curve of using the Centre-adaptive multi-modal fusion framework (Cad-MMFF)

Timeframe: Through study completion, an average of 1 year

The number of unnecessary biopsy rate decreased of using the Centre-adaptive multi-modal fusion framework (Cad-MMFF)

Timeframe: Through study completion, an average of 1 year

Proportion of MRI safely saved of using the Centre-adaptive multi-modal fusion framework (Cad-MMFF)

Timeframe: Through study completion, an average of 1 year

Net-Benefit of using the Centre-adaptive multi-modal fusion framework (Cad-MMFF)

Timeframe: Through study completion, an average of 1 year

Missed rate of clinically significant prostate cancer of using the Centre-adaptive multi-modal fusion framework (Cad-MMFF)

Timeframe: Through study completion, an average of 1 year

Detection rate of indolent prostate cancer of using the Centre-adaptive multi-modal fusion framework (Cad-MMFF)

Timeframe: Through study completion, an average of 1 year

Trial details

NCT IDNCT07760857

SponsorChinese University of Hong Kong

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-09-01

Contact for this trial

Chi Fai NG, MBChB, FRCS (Surg), MD

852-3505-2625 ngcf@surgery.cuhk.edu.hk

View on ClinicalTrials.gov More Prostate Cancer (Diagnosis) trials

Who can participate

Age range

45 Years

Sex

MALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Area under Receiver-Operating-Curve of using the Centre-adaptive multi-modal fusion framework (Cad-MMFF)

Timeframe: Through study completion, an average of 1 year

The number of unnecessary biopsy rate decreased of using the Centre-adaptive multi-modal fusion framework (Cad-MMFF)

Timeframe: Through study completion, an average of 1 year

Proportion of MRI safely saved of using the Centre-adaptive multi-modal fusion framework (Cad-MMFF)

Timeframe: Through study completion, an average of 1 year

Net-Benefit of using the Centre-adaptive multi-modal fusion framework (Cad-MMFF)

Timeframe: Through study completion, an average of 1 year

Missed rate of clinically significant prostate cancer of using the Centre-adaptive multi-modal fusion framework (Cad-MMFF)

Timeframe: Through study completion, an average of 1 year

Detection rate of indolent prostate cancer of using the Centre-adaptive multi-modal fusion framework (Cad-MMFF)

Timeframe: Through study completion, an average of 1 year